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Abstract 
 
 
Cerebral ischemia is encompassed by cerebrovascular apoptosis, yet the 
mechanisms behind apoptosis regulation are not fully understood. We previously 
demonstrated inhibition of endothelial apoptosis by vascular endothelial growth factor 
(VEGF) through upregulation of poly(ADP-ribose)-polymerase (PARP) expression. 
However, PARP overactivation through oxidative stress can lead to necrosis. This 
study tested the hypothesis that neuropilin-1 (NP-1), an alternative VEGF receptor, 
regulates the response to cerebral ischemia by modulating PARP expression and, in 
turn, apoptosis inhibition by VEGF. In endothelial cell culture, NP-1 colocalized with 
VEGF receptor-2 (VEGFR-2) and acted as its coreceptor. This significantly enhanced 
VEGF-induced PARP mRNA and protein expression demonstrated by receptor- 
specific inhibitors and VEGF-A isoforms. NP-1 augmented the inhibitory effect of 
VEGF/VEGFR-2 interaction on apoptosis induced by adhesion inhibition through the 
αV-integrin inhibitor cRGDfV. NP-1/VEGFR-2 signal transduction involved JNK and 
 
Akt. In rat models of permanent and temporary middle cerebral artery occlusion, the 
ischemic cerebral hemispheres displayed endothelial and neuronal apoptosis next to 
increased endothelial NP-1 and VEGFR-2 expression compared to non-ischemic 
cerebral  hemispheres,  sham-operated  or  untreated  controls.  Increased  vascular 
superoxide dismutase-1 and catalase expression as well as decreased glycogen 
 
reserves indicated oxidative stress in the ischemic brain. Of note, protein levels of 
 
intact  PARP  remained  stable  despite  pro-apoptotic  conditions  through  increased 
 
PARP mRNA production during cerebral ischemia. In conclusion, NP-1 is 
upregulated in conditions of imminent cerebrovascular apoptosis to reinforce 
apoptosis inhibition and modulate VEGF-dependent PARP expression and activation. 
We propose that NP-1 is a key modulator of VEGF maintaining cerebrovascular 
integrity during ischemia. Modulating the function of NP-1 to target PARP could help 
to prevent cellular damage in cerebrovascular disease. 
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Abbreviations 
A7R, neuropilin-1 inhibitor [ATWLPPR]; Bcl-2, B-cell lymphoma 2 protein; BSA, 
bovine serum albumin; cRGDfV, αV-integrin inhibitor cyclo-[Arg-Gly-Asp-D-Phe-Val]; 
EC,   endothelial   cells;   GAPDH,   glyceraldehyde-3-phosphate   dehydrogenase; 
%HLVec, edema-corrected ischemic lesion volume; HUVEC, human umbilical vein 
endothelial cells; IR, ischemia-reperfusion model; IO,  ischemia-occlusion  model; 
ISL assay, in situ-ligation assay; MCAO, middle cerebral artery occlusion; NF-κB, 
nuclear  factor   κ-light-chain-enhancer   of   activated   B-cells;   NP-1,   neuropilin-1; 
PARP, poly(ADP-ribose)-polymerase; PAS, periodic acid-Schiff reaction staining; 
SOD-1, superoxide dismutase-1; STATs, signal transducers and activators of 
transcription; SU5416, tyrosine-kinase inhibitor of vascular endothelial growth factor 
receptor-2 [3-[(2,4-di-methylpyrrol-5-yl)-methylidene]-indolin-2-one]; VEGF, vascular 
endothelial growth factor; VEGFR-2, vascular endothelial growth factor receptor-2. 
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Introduction 
 
Neuropilin-1 (NP-1) is an alternative receptor for vascular endothelial growth factor 
(VEGF) (Soker et al. 1998). NP-1 functions as a coreceptor to VEGF receptor-2 
(VEGFR-2), the main receptor for VEGF on vascular endothelial cells (EC) (Petrova 
et al. 1999). NP-1 potentiates the effects of VEGF-A(165) binding to VEGFR-2 by 
increasing the cellular response to VEGF (Soker et al. 1998) and by generating a 
stronger VEGFR-2 signal (Ballmer-Hofer et al. 2011). Among the VEGF family 
members, VEGF-A is the strongest apoptosis-inhibiting factor of EC with several 
splice variants (121, 145, 165, 189, and 206 amino acids) that show different 
receptor affinities. VEGF-A(165) promotes EC survival, proliferation and migration, 
but also vascular permeability (Zachary 2001). The cerebrovascular endothelium is 
 
prominently involved in many processes with high impact on cerebral ischemia and 
 
stroke, such as blood-brain barrier integrity, regulation of arterial tone, inflammation, 
 
perfusion and thrombosis (Broughton et al. 2009; Dirnagl et al. 1999). Reduced 
 
cerebrovascular perfusion leads to an impairment of the blood-brain-barrier that is 
 
reversible, when the cerebral blood flow is restored before cellular damage occurs 
 
(Dirnagl et al. 1999). Longer lasting interruptions in perfusion lead to apoptosis of the 
 
vascular endothelium (Li et al. 1995) encompassing the breakdown of the blood- 
 
brain-barrier with consequent cerebral edema, hemispheral swelling and neuronal 
 
damage  (Dirnagl  et  al.  1999;  Gerriets  et  al.  2004).  Physiological  mechanisms 
 
inhibiting endothelial apoptosis therefore not only increase endothelial resistance to 
 
pro-apoptotic stimuli, but also support vascular and neuronal integrity (Fisher 2008). 
 
 
 
 
A deeper knowledge on vascular apoptosis in cerebral ischemia is warranted to 
 
identify   new   therapeutic   targets   in   stroke   management.   This   implicates 
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characterization of the features of apoptosis and cell survival in cerebral vascular 
 
cells (Broughton et al. 2009). Apoptosis and cell survival are subject to complex 
regulation by pro- and anti-apoptotic factors. EC survival is governed by growth 
factors like VEGF and also by adhesion molecules such as integrins (Zachary 2001). 
Apoptosis in EC and vascular smooth muscle cells is induced through the inhibition 
of cellular adhesion with subsequent activation of caspase-3, as we have previously 
demonstrated (Al-Fakhri et al. 2003a). Caspase-3 transduces apoptosis-inducing 
signals to the nucleus and induces typical apoptotic features such as DNA 
degradation by endonucleases or inhibition of DNA repair through cleavage of 
poly(ADP-ribose)-polymerase (PARP). PARP is a nuclear DNA-binding enzyme that 
supports DNA strand break repair and counteracts pro-apoptotic deoxyribonucleases 
(Duriez and Shah 1997). 
One of the mechanisms, by which endothelial apoptosis is prevented physiologically 
 
is  a  VEGF-dependent  induction  of  PARP  expression  and  activity,  as  we  have 
 
previously demonstrated (Hörmann et al. 2011). PARP is also involved in 
inflammation and oxidative stress (Virag 2005; Aguilar-Quesada et al. 2007) by 
modulating the activity of several transcription factors as promoter binding cofactor, 
like p53, nuclear factor κ-light-chain-enhancer of activated B-cells (NF-κB),  and 
signal transducers and activators of transcription (STATs). The role of PARP in cell 
death and inflammatory responses depends on the cellular activation state. In 
oxidative stress situations with excessive and irreparable DNA damage, such as 
acute inflammation, shock, or severe ischemia, overactivation of PARP leads to 
intracellular ATP depletion resulting in necrosis. In the absence of overactivation, 
PARP conveys cellular protection (Virag 2005; Aguilar-Quesada et al. 2007). 
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The mechanisms behind apoptosis inhibition and regeneration of cerebrovascular 
integrity in cerebral ischemia remain to be identified. We hypothesized that NP-1 
modulates VEGF-dependent processes by adapting the cellular response to 
VEGF/VEGFR-2 mediated signaling and by regulating PARP expression. In this 
study, we show that NP-1 is an important modulator of VEGF/VEGFR-2-induced 
apoptosis inhibition in cerebral ischemia and a regulator of PARP expression 
influencing cell survival. NP-1 could therefore act as a protective vascular receptor 
during cerebrovascular insults. 
 
 
 
 
 
 
Material and methods 
 
Animals and MCAO model 
 
Ischemia was assessed using a permanent and a temporary middle cerebral artery 
occlusion (MCAO) model, as described previously (Gerriets et al. 2004). Seventeen 
male Wistar rats (290 to 350 grams; Harlan Winkelmann, Borchen, Germany) were 
randomly subjected to different treatment groups: (a) ischemia through MCAO for 90 
minutes, followed by reperfusion (IR) after 90 minutes (n=8) compared to (b) sham- 
operation (n=5). These were supplemented by the groups (c) permanent ischemia 
through MCAO occlusion (IO) (n=3) and (d) untreated control animal (n=1). In IR, 90 
minutes occlusion time was chosen, since this time period of ischemia followed by 
reperfusion has previously been shown to be the time point for the induction of 
apoptosis in the vascular endothelium (Li et al. 1995). Animals were anesthetized 
with 5% isoflurane delivered in air at 3.0 l/min for 2 min, followed by 2–3% isoflurane 
delivered in air at 0.5 l/min. The right external carotid artery was ligated and 
transsected, a 4-0 silicone–coated nylon suture was inserted through the external 
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carotid artery stump and advanced into the internal carotid artery beyond the carotid 
bifurcation until reaching the anterior cerebral artery, so that blood flow to the MCA 
was blocked. Reperfusion was induced in IR-animals by removing the suture 90 
minutes  after  MCAO.  Neurological  evaluation  was  performed  at  0,  4  and  24  h 
(Gerriets et al. 2004) by a clinical score utilizing ten different motor, coordinative and 
 
sensory functions and additionally by the Rotarod test for motoric function (Nedelman 
 
et al. 2007). After 24 hours, animals underwent MRI (Bruker PharmaScan 7.0T, 16 
cm) under isoflurane anesthesia to determine ischemic lesion size. T2-relaxation- 
time as a marker for brain water content and lesion-related midline shift were 
measured to quantify vasogenic edema formation. Computer-aided planimetric 
assessment of the lesion and hemispheric volumes were performed using image 
analysis software Image J (National Institutes of Health, NIH), regions of interest in 
qT2 were defined in the ischemic lesions with PharmaScan software 5.1 (Bruker). 
The edema-corrected ischemic lesion volume (%HLVec) was calculated from the  
infarct volume [cm3] relative to the hemispheric volumes [cm3] and then scaled to 
100%  (Gerriets  et  al.  2004).  After  MRI,  animals  were  deeply  anesthetized  and 
euthanized. The brains were removed, snap-frozen and analyzed. 
 
 
 
Ethics 
 
All procedures were in accordance with the uniform requirements for manuscripts 
submitted to biomedical journals (http://www.icmje.org). Animal experimentation was 
approved by the responsible legislative authority and complied with EU animal 
protection legislation (EU Directive 2010/63/EU for animal experiments, 
http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm). 
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Cell cultures 
 
Human umbilical vein EC (HUVEC) (PromoCell), the macrovascular EC line 
EA.hy.926 and brain microvascular line hCMEC/D3 were cultivated for 2 days (d) to 
60-70% confluence with endothelial growth medium without VEGF supplement 
(Promocell), thereafter incubated as follows: 
 
 
 
Incubation protocols 
 
HUVEC, EA.hy.926 and hCMEC/D3 (for flow cytometry) were incubated with 
recombinant human homo-dimeric VEGF-A(165) or VEGF-A(121) 1-100ng/ml (5x10- 
11 - 5x10-9M) (Peprotech) over 16 hours (h) to 24h for mRNA isolation, over 20h for 
 
apoptosis detection, or over 24h to 6d (with repeated incubations at intervals of 48h) 
for protein isolation, respectively. These incubation periods were determined in 
preceding experiments (Hörmann et al. 2011) 
 
After stimulation with VEGF that increases the apoptotic threshold (Hörmann et al. 
2011), apoptosis was induced by incubation with αV-integrin inhibitor cRGDfV (cyclo- 
[Arg-Gly-Asp-D-Phe-Val]) 5µg/ml (Bachem) for 24h inhibiting adhesion to vitronectin 
(2µg/ml)-coated multiwell plates, blocked with 3% BSA (Al-Fakhri et al. 2003a). 
 
To analyze the function of NP-1 and VEGFR-2, the above mentioned cells were 
incubated with VEGF-A(165) 10ng/ml in the presence or absence of the peptide 
inhibitor of NP-1 A7R [ATWLPPR] (Bachem) 10µM and/or the selective VEGFR-2 
tyrosine-kinase inhibitor SU5416 [3-[(2,4-dimethylpyrrol-5-yl)-methylidene]-indolin-2- 
one] (Calbiochem) 10µM in the presence or absence of cRGDfV 5µg/ml. 
 
VEGF signal transduction was studied by VEGF-A(165) 100pg/ml-100ng/ml 
incubation over short time intervals (15-30-60-120min). Involvement of Akt and JNK 
was analyzed by incubation with Akt inhibitors triciribine 10µM, isozyme-selective 
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Akti-1/2 1µM or SAPK/JNK inhibitor SP600125 10µM (Calbiochem), respectively, 
and VEGF-A(165) 1ng/ml-100ng/ml. 
 
Transcriptional or translational regulation was analyzed by incubating EC with VEGF- 
 
A(165) 10ng/ml and actinomycin D (AD) 1µg/ml or  cycloheximide (CHX) 2µg/ml 
 
(Sigma-Aldrich).   Additionally,   coincubations   were   carried   out   using   different 
 
combinations of AD or CHX with VEGF receptor and kinase inhibitors. 
 
 
Controls were conducted in parallel to all experiments using only EC medium 
(negative control), VEGF-A(165) 10-100ng/ml (VEGF control), cRGDfV (apoptosis 
control), or VEGF receptor and signaling inhibitors, respectively. 
 
 
 
Apoptosis detection 
 
Apoptosis was quantified in cultivated cells by annexin V-FITC/propidium iodide 
(Immunotech) flow cytometry of 20000 cells/measurement (FACSort, BD 
Biosciences), as previously described (Hörmann et al. 2011). Apoptotic cells were 
considered annexin V-positive/propidium iodide-negative signals within pre-defined 
gating criteria. 
In rat brain, apoptosis was detected by in situ-ligation assay (ISL) as described 
previously (Schoppet et al. 2004). It demonstrates the apoptosis-specific form of DNA 
fragmentation, i.e. 3' single-base overhang, double-stranded DNA breaks. Briefly, a 
specific DNA probe was prepared by PCR and purified. Brain transverse cryostate 
sections (6µm) were acetone-fixed, treated with proteinase K 20 µg/mL, then 
incubated with the digoxigenin (DIG)-labelled DNA fragment and DNA T4 ligase 
(Sigma) in a humidified chamber for 1 h at room temperature. For negative control, 
the DIG-labelled DNA fragment was omitted, for positive control, one slide was 
pretreated  with  DNAse  I.  Probe  binding  was  detected  by  sheep  anti-DIG  Fab- 
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antibody conjugated to alkaline phosphatase (Roche, Mannheim, Germany, 1:500). 
Color development was performed with NBT/BCIP (nitroblue tetrazolium/5-bromo-4- 
chloro-3-indolyl phosphate) and 1 mM levamisole (Sigma) for 70 min. 
 
 
 
Western Blot 
 
Protein was isolated with AllPrep RNA/protein kit (Qiagen) for cells or RIPA buffer 
(50mM Tris pH 8,0 containing 150mM NaCl, 1% NP-40, 0,5% sodium deoxycholat, 
0,1% SDS, protease inhibitor, Complete, Roche) for tissue lysates. Protein 
concentration was determined with bicinchoninic acid reagent (Thermo-Scientific) 
followed by electrophoresis and blotting (Hörmann et al. 2011). Primary antibodies 
employed were rabbit anti human NP-1 (monoclonal, Epitomics, 1:1000) and goat- 
anti-human PARP (R&D-Systems, 0.4µg/ml). All blots were normalized to β-actin as 
loading control stained with mouse-anti-β-actin (clone AC-15, Sigma, 1:20.000). 
Signal transduction molecules were detected with rabbit antibodies against B-cell 
lymphoma 2 protein (Bcl-2), Akt, phospho-Akt (Ser473/Thr308), SAPK/JNK, 
phospho-SAPK/JNK (Thr183/Tyr185), ERK1/2, phospho-ERK1/2 (Thr202/204), p38 
MAPK, and phospho-p38 MAPK (Thr180/Tyr182) (Cell Signaling, 1:500). Western 
blots were evaluated by automated densitometry using the gel analyzing function of 
Image J software (NIH), as previously described (Gassmann et al. 2009). In Bcl-2 
blots, only one specific band was detected and evaluated. In NP-1 blots, the 130 kDa 
band representing the membrane-bound receptor was evaluated, other bands at 90 
and 75 kDa representing soluble NP-1 without receptor function (Gagnon et al. 2000; 
Cackowski et al. 2004) found in individual IR and IO animals were excluded from 
analysis. In PARP blots, the band at 116 kD corresponding to intact PARP was 
 
evaluated.  In  protein  isolated  from  rat  brain,  the  bands  at  89  and  24  kD 
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corresponding to PARP cleavage products that are found in apoptotic specimens 
 
(Hörmann  et  al.  2011;  Boulares  et  al.  1999)  were  additionally  evaluated,  since 
 
apoptosis was present in the IR and IO model. 
 
 
 
 
Real-time RT-PCR 
 
PARP-1 mRNA was quantified by real-time polymerase chain reaction (PCR) using 
 
Rotorgene (Corbett). mRNA from cells or tissue was isolated with AllPrep 
RNA/protein kit (Qiagen) or TriFast reagent (Peqlab) and the concentration 
calculated from OD260. After DNAse I (Invitrogen) treatment and inactivation, reverse 
transcription (RT) was performed with Omniscript RT kit (Qiagen). PARP-1 real-time 
PCR was conducted as recently described (Hörmann et al. 2011). 
PARP-1 copy numbers, calculated from threshold cycle (CT) values, were determined 
by means of serially diluted external standards that were synthesized by PCR and 
subsequent purification (Al-Fakhri et al. 2003b) and by ∆∆ CT method. Results were 
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA for cell 
culture  experiments  and  to  lamin  A/C  (LMNA  primers,  Qiagen)  for  brain  tissue. 
 
Expression stability in EC cultures of the house keeping gene under pro-apoptotic 
conditions and VEGF stimulation was determined in previous studies (Hörmann et al. 
2011;  Al-Fakhri  et  al.  2003b).  In  cerebral  ischemia  and  reperfusion,  GAPDH  is 
 
upregulated in neurons (Tanaka et al. 2002). We therefore employed lamin A/C 
 
(Jung et al. 2012) as a house keeping gene for brain tissue analyses, since RNA was 
 
derived from whole tissue homogenates containing all brain cells. 
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Immunocyto- and immunohistochemistry 
 
HUVEC grown on vitronectin-coated (2µg/ml) glass cover slips were incubated in the 
presence or absence of VEGF-A(165) 10ng/ml for 2d. Cells were fixed with 4% 
formaldehyde/PBS, incubated with Image-iT FX-signal enhancer (Invitrogen), then 
with mouse-anti-human VEGFR-2 (Santa Cruz, clone Y-23, 1µg/ml) and rabbit-anti- 
human NP-1 (5µg/ml) antibodies 16h at 4°C, thereafter with Alexa Fluor 488- and 
Cy3-labeled secondary antibodies 1h and DAPI 2µg/ml 20min, finally covered with 
ProLong Gold antifade reagent (all Invitrogen). Negative controls were conducted 
with an irrelevant primary antibody or PBS. Immunofluorescence was analyzed by 
means of an AxioVision microscope with optical sectioning using ApoTome.2 
structured illumination technology (Zeiss). 
 
 
 
Transverse cryostat sections (6µm) were acetone-fixed, incubated with 5% normal 
serum/PBS, then with primary antibodies: goat anti-PARP (R&D-Systems, 1:20), goat 
anti-VEGF (R&D-Systems, 1:50), mouse anti-VEGFR-2 (Santa Cruz, clone Y-23, 
1µg/ml), rabbit anti-NP-1 (Invitrogen, 5µg/ml), rabbit anti-cleaved caspase-3 (R&D- 
Systems,1:1000), goat anti-catalase (R&D Systems, 0,5µg/ml) or rabbit anti- 
superoxide dismutase-1 (SOD-1) (Santa Cruz, FL-154, 10µg/ml) as markers of 
oxidative stress, rabbit anti-von-Willebrand-factor (Dako, 1:200) for 2-16h at 4°C. 
Subsequently, slides were incubated with biotinylated secondary antibodies, 
streptavidin-alkaline phosphatase-conjugate, Fast Red, and Mayer's haemalum (all 
Sigma). Negative controls were conducted with an irrelevant primary antibody or 
PBS. Immunostaining was semiquantitatively evaluated by two investigators. 
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Sections of rat brain tissue were investigated for glycogen content by PAS (periodic 
 
acid-Schiff reaction) staining (Kong et al. 2002) to demonstrate energy depletion 
 
caused by ischemia (Brucklacher et al. 2002). Stained whole-mount sections were 
 
scanned, red PAS staining was converted to grey scale and densitometrical analysis 
 
was carried out with Image J software (NIH) (Kong et al. 2002). 
 
 
 
 
Statistics 
 
For all analyses, 3 to 7 independent experiments were performed in triplicate (PCR) 
or duplicate (all other experiments) and results were expressed as mean +/- standard 
error of the mean (SEM). Significance of differences was tested a) by unpaired, two- 
 
tailed Student's t-test and additionally b) by two-way-ANOVA analysis with Bonferroni 
 
correction.  Both  statistical  methods  showed  concordant  results  in  all  analyses; 
 
p<0.05  was  considered  as  significant  difference,  p<0.01  as  highly  significant 
 
difference. 
 
Histological specimens were evaluated semi-quantitatively by light microscopy at 
200-fold magnification through two experienced investigators independently: 
Immunohistochemical data were analyzed by counting the number of positive cells 
(with a specific staining) and identifying the cell type. The apoptotic index was 
determined by counting the number of ISL positive (dark-blue) nuclei. Analyses were 
carried out in four fields of view at 200-fold magnification per hemisphere and 
calculating the mean percentage +/- SEM, respectively. 
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Results 
 
 
NP-1 increases apoptosis inhibition induced by VEGF/VEGFR-2 interaction 
Preincubation with VEGF-A(165) 1-100ng/ml resulted in a significant reduction of the 
apoptotic rate compared to non-VEGF-treated EC. VEGF-A(165) increased 
endothelial resistance to apoptosis induced by cRGDfV that inhibits integrin binding 
to the vitronectin matrix in HUVEC (Figure 1A) and EA.hy.926 cells. The strongest 
increase in apoptosis resistance was demonstrated for pre-incubation with VEGF- 
A(165) over 6d (at 48h-intervals) compared to 24h, matching our previous results 
(Hörmann et al. 2011). These results were reproduced in human cerebrovascular 
hCMEC/D3 cells. Preincubation with VEGF-A(121) reduced EC apoptosis induced by 
cRGDfV  significantly  less  than  VEGF-A(165),  yet  increased  the  resistance  to 
apoptosis  (Figure  1A).  VEGF-A(121)  binds  predominantly  to  VEGFR-2,  but  has 
 
neglectable binding affinity for NP-1, whereas VEGF-A(165) binds both receptors 
 
(Zachary 2001). The binding affinity of VEGF-A(165) is slightly higher for VEGFR-2 
 
than  for  NP-1,  however,  VEGF-A(165)  will  preferentially  bind  to  VEGFR-2/NP-1 
 
complexes  leading  to  an  increased  potency  of  VEGF-A(165)  over  VEGF-A(121) 
 
(Whitaker et al 2001). Incubation with VEGF-A(165) alone had no influence on the 
apoptotic rate, whereas VEGF-A(121) slightly increased apoptosis compared to the 
negative control (Figure 1A). Incubations with receptor inhibitors SU5416 10µM 
and/or A7R 10µM, selective antagonists of VEGFR-2 or NP-1, respectively, revealed 
that blocking NP-1 had no significant influence on the induction of apoptosis 
resistance through VEGF-A(165) in the presence of cRGDfV. However, simultaneous 
inhibition of VEGFR-2 and NP-1 or blocking VEGFR-2 alone, respectively, abolished 
the apoptosis inhibiting effect of VEGF (Figure 1B). Therefore, NP-1 signaling alone 
in  the  presence  of  VEGFR-2  inhibitor  could  not  prevent  apoptosis  induction 
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consistent with a VEGFR-2 coreceptor role for NP-1, as explained in detail in the 
 
discussion section. The inhibitor SU5416 is selective for VEGFR-2 (IC50 = 1.04 µM) 
 
(Fong et al. 1999). A7R is an inhibitor of NP-1 (IC50 = 630 nM) that was first 
 
described  to  bind  to  VEGFR-2.  However,  detailed  studies  revealed  a  selective 
 
inhibition of NP-1 binding to VEGF by A7R and no inhibition of VEGFR-2 binding 
 
(Perret et al. 2004). Negative control, A7R inhibitor control (Figure 1B) or incubations 
only with VEGF-A(165) (data not shown) displayed minimal apoptotic rates. 
Incubation with SU5416 alone or A7R together with SU5416 with or without VEGF 
showed a small, non-significant change in the apoptotic rate compared to the 
negative control (Figure 1B). Taken together, NP-1 augmented the anti-apoptotic 
VEGF effect conveyed through VEGF/VEGFR-2 interaction as demonstrated by 
incubations with VEGF isoforms, but importantly, NP-1 did not exert an independent 
apoptosis-inhibiting effect rather acted as a VEGFR-2 coreceptor, as shown by 
inhibitor experiments. 
 
 
 
NP-1 augments the induction of PARP expression by VEGF 
 
Incubation with VEGF-A(165) 1-100ng/ml over 6d at 48h-intervals caused a 
significantly higher increase in intact PARP protein (116kD), maximum 120%, 
compared to incubation with VEGF-A(121) 1-100ng/ml, maximum 80%, as 
demonstrated by Western blot densitometry normalized to β-actin in HUVEC (Figure 
2A). Real-time RT-PCR revealed a significant, 270% increase in PARP-1 mRNA 
production normalized to the house keeping gene GAPDH mRNA after incubation 
with VEGF-A(165) for 16h compared to negative control preceding the increase in 
PARP protein. VEGF-A(121) induced a 180% increase in PARP mRNA that was 
smaller  than  the  VEGF-A(165)  effect  (Figure  2A).  Therefore,  binding  of  both 
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receptors  by  VEGF-A(165)  induced  a  significantly  higher  increase  in  PARP 
 
expression than binding of predominantly VEGFR-2 by VEGF-A(121) consistent with 
 
NP-1's role as a VEGFR-2 coreceptor. 
 
 
 
 
Incubation with VEGF-A(165) and the VEGFR-2 inhibitor SU5416 showed a 
significant reduction of PARP protein expression compared to incubation with VEGF- 
A(165) alone in HUVEC (Figure 2B). Coincubation of VEGF-A(165) with the NP-1 
inhibitor A7R (in the absence of VEGFR-2 inhibition) had no significant impact on the 
increase in PARP protein expression induced by VEGF in comparison to incubation 
with VEGF-A(165) alone. In contrast, combined incubation of VEGF-A(165) with A7R 
and SU5416 further reduced PARP protein compared to incubation with VEGF and 
SU5416 (Figure 2B). Incubations with A7R and/or SU5416 alone (inhibitor controls) 
had no effect on PARP protein expression (Figure 2B). The increase in PARP-1 
mRNA production (normalized to GAPDH mRNA) through incubation with VEGF- 
A(165) only was significantly reduced by coincubation of VEGF with SU5416, with 
A7R or with both inhibitors, respectively (Figure 2B). Inhibitor controls showed no 
influence on PARP mRNA production. Thus, NP-1 was demonstrated to augment 
VEGF-dependent induction of PARP expression as a coreceptor to VEGFR-2. These 
results were reproduced in the EC line EA.hy.926. 
 
 
 
VEGF has previously been described to induce the intracellular apoptosis inhibitor 
Bcl-2 thereby reducing endothelial apoptosis (Gerber et al. 1998). In the present 
study, incubation with VEGF-A(165) 10ng/ml produced a 20% increase in Bcl-2 
protein that did not reach statistical significance. This increase was smaller than the 
significant elevation in PARP expression induced by VEGF-A(165) (Figure 2C). This 
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finding underlined the relevance of the VEGF effect on PARP expression as 
compared to Bcl-2 expression in the context of apoptosis inhibition. 
 
 
 
VEGF-dependent signal transduction leading to the induction of PARP expression 
was found to be mediated by phosphorylation of Akt and JNK, as demonstrated by 
Western blot of phosphorylated kinase correlated to total kinase. MAPK p38 and 
ERK1/2 did not show phosphorylation following stimulation with VEGF-A(165) (Figure 
2D). These results were supported by experiments with Akt inhibitors triciribine and 
Akti-1/2 as well as SAPK/JNK inhibitor SP600125 incubated with VEGF-A(165). 
Therefore, VEGF-A(165) signaling via VEGFR-2 and NP-1 is conveyed by Akt and 
JNK activation. 
 
 
The level of PARP regulation by VEGF, whether transcriptional or translational, was 
 
investigated by AD or CHX, respectively. AD significantly inhibited PARP protein and 
 
mRNA upregulation by VEGF, whereas CHX did not significantly alter PARP protein 
 
or mRNA regulation by VEGF (Figure A online supplement). Incubation with AD only 
 
reduced PARP protein expression, whereas CHX had no significant effect on PARP 
 
compared to control. Thus, VEGF exhibited its effect on PARP gene expression via 
VEGFR-2 and NP-1 on the transcriptional and not on the translational level. 
 
 
 
NP-1 expression colocalizes with VEGFR-2 upon VEGF stimulation and is 
abolished by apoptosis 
VEGFR-2 and NP-1 were expressed on the cell membrane and uniformly distributed 
in the cytoplasm of HUVEC cultivated without VEGF supplement (Figure 3). The 
receptors showed colocalization at several sites of the cell surface, demonstrated by 
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immunofluorescence using 3D-scanning technique of an optical sectioning 
microscopic device. Upon stimulation with VEGF, NP-1 colocalized extensively with 
VEGFR-2, the receptors clustered on the cell surface and in the perinuclear space, 
supporting the VEGFR-2 coreceptor function of NP-1 (Figure 3). Interestingly, in EC 
undergoing apoptosis induced by adhesion inhibition with cRGDfV, immuno- 
detectable NP-1 was dramatically reduced and VEGFR-2 distribution was changed to 
a disseminated, less intense staining pattern. Only few perinuclear receptor clusters 
containing colocalized NP-1 and VEGFR-2, probably rests of endocytosed receptor 
clusters, could be demonstrated in cells undergoing apoptosis (Figure 3). Results in 
EA.hy.926 cells were comparable. This indicated an organizational and functional 
loss of VEGF receptor integrity in cells undergoing apoptosis. 
 
 
 
Cerebral ischemia is associated with increased NP-1 and PARP expression and 
related to endothelial apoptosis 
The in-vitro data were corroborated by a permanent (IO) and a temporary (IR) rat 
cerebral ischemia model that were characterized by neuronal and endothelial 
apoptosis in the ischemic hemisphere, as identified by ISL assay (Figure 4). Both 
models showed vasogenic brain edema on the ischemic side, accompanied by tissue 
destruction that was more prominent in the IO model. The edematous lesions 
corresponded to the lesions found on MRI. In the IR model that underwent 
reperfusion after 90 minutes, the number of apoptotic endothelial and neuronal cells 
was significantly increased in the ischemic hemisphere as compared to either the 
contralateral hemisphere or sham-operated and untreated controls (Figure 4). 
Individual apoptotic nuclei were detected in the contralateral hemisphere in the 
vicinity of the cerebral midline, possibly as a consequence of the space occupying 
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effect due to vasogenic edema formation. Comparable results were demonstrated for 
IO, however, IR showed a higher rate of apoptotic cells than IO (Figure 4), possibly 
due to the more pronounced tissue destruction in the ischemic hemisphere of the IO 
model as seen on the histological sections. This might have reduced the number of 
vessels and neurons detectable by ISL assay in the IO model leading to an only 
seemingly lower apoptotic rate. 
 
 
 
Neurological evaluation and scoring performed at 0, 4 and 24 h as well as cerebral 
MRI after 24 h, evaluating T2-relaxation-time and midline shift, revealed clinical and 
radiological signs of cerebral ischemia with ensuing vasogenic edema formation and 
cerebral  infarction  in  IR  or  IO  exposed  animals.  Mean  ischemic  lesion  volume 
 
%HLVec, determined by planimetric analysis of MRI at time point 24 h (Gerriets et al. 
 
2004), was 31.5% ± 18.7% in the IO group and 37.0% ± 10.1% in the IR group. The 
 
midline shift at time point 24 h was 0.068 +/- 0.0168 cm in the IO group vs. 0.102 +/- 
 
0.0336cm in the IR group. There were no statistical differences between the groups 
 
(p>0.05). However, these values were significantly different from sham- and non- 
 
operated control animals: mean ischemic lesion volume: 0.0% ± 0.0% and midline 
 
shift: -0.012 +/- 0.0198 cm. Clinical scores (Nedelman et al. 2007) after MCAO of the 
IO and IR groups were significantly different from sham- and non-operated animals 
(p<0.01). 
 
 
 
Brain sections analyzed by immunohistochemistry showed increased expression of 
NP-1 and VEGFR-2 in the endothelium and of NP-1 in neurons of the ischemic 
hemisphere in IO and IR models (Figure 5A). In the IR model, NP-1 expression of 
neurons and the endothelium was higher on the ischemic than on the contralateral 
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side, however, only the number of NP-1 positive vessels was significantly different 
(Figure 5A, 5B). In IO and IR, we generally observed a significantly higher vascular 
NP-1 expression in regions of endothelial apoptosis compared to brains of non- 
operated and sham-operated animals. VEGFR-2 showed a similar expression pattern 
as NP-1 in vascular structures in the IO and IR model with an increased VEGFR-2 
expression on the ischemic compared to the contralateral side, but no VEGFR-2 
expression in neurons (Figure 5A). PARP immunostaining was increased in the IO 
and IR model in both hemispheres in the endothelium as well as in neurons 
compared to sham-operated and non-operated animals (Figure 5A). In the IR model, 
PARP immunostaining was significantly higher in the neurons on the ischemic side 
than on the contralateral side. In EC, there was no difference between the 
hemispheres (Figure 5B). However, the PARP antibody detects intact PARP and its 
degradation products so that an increased PARP immunostaining might also be due 
to neuronal apoptosis induction in the ischemic region accompanied by an increase 
in PARP degradation products. VEGF expression of pial and glial cells as well as 
individual neurons in the ischemic hemisphere and weaker in the contralateral 
hemisphere was demonstrated. In the ischemic hemisphere, increased 
immunostaining of activated (cleaved) caspase-3, catalase (Figure 5A) and SOD-1 
expression were found. Von Willebrand factor staining demonstrated the integrity of 
the endothelial lining (Figure 5A). 
 
 
 
Whole tissue lysates prepared separately from both hemispheres of every individual 
animal showed an increased NP-1 protein expression in the IR model compared to 
the controls as demonstrated by densitometry of Western blots. NP-1 expression was 
higher in the contralateral hemisphere of the IR model compared to the ischemic 
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hemisphere (Figure 5C). However, the tissue lysates consisted of whole brain tissue 
 
and did not allow for differentiation of cell types. Mean values of intact PARP protein 
 
(116 kD) were almost identical on both sides and remained unaltered compared to 
 
the control animals (p>0.05). However, PARP degradation products 89 and 24 kD 
 
were increased, especially in the ischemic hemisphere (Figure 5C). Note that an 
unchanged expression of intact PARP 116 kD under the pro-apoptotic conditions of 
ischemia indicates a net increase in PARP expression, since PARP is degraded 
 
immediately during apoptosis induction mainly into the cleavage products 89 and 24 
 
kD (Duriez and Shah 1997; Boulares et al. 1999) that were moderately increased 
 
here. PARP mRNA production (normalized to lamin A/C mRNA) was significantly 
 
increased in the IR model in the ischemic as well as in the contralateral hemisphere 
 
compared to sham-operated and control animals (Figure 5D), supporting the results 
 
on the protein level indicating a net increase in PARP production. 
 
 
 
 
Oxidative stress caused by cerebral ischemia can lead to cellular energy depletion. 
 
Glycogen is an important energy reserve of the brain  (Brucklacher et al. 2002). 
 
Whole-mount cryostate sections of brain tissue from the IR model, sham-operated 
 
and control animals were analyzed for the glycogen content by PAS (periodic acid- 
 
Schiff reaction) staining and computer-assisted evaluation of scanned sections (Kong 
 
et  al.  2002).  The  mean  glycogen  content  of  ischemic  hemisphere  of  IR  model 
 
animals was significantly reduced compared to control, however, the contralateral 
 
hemispheres and sham-operated animals also showed slightly reduced glycogen 
 
content  compared  to  control  (Figure  6).  The  whole  ischemic  hemisphere  was 
 
evaluated for glycogen content, so the mean value represents the ischemic region as 
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well as the non-ischemic tissue. The ischemic region showed almost no PAS staining 
 
(Figure 6), indicating a loss of glycogen reserves and energy depletion in this region. 
 
 
 
 
In summary, NP-1, VEGFR-2 and PARP are increased in cerebral ischemia in the 
context of oxidative stress and imminent vascular and neuronal apoptosis. 
 
 
 
 
 
 
Discussion 
 
 
Protective therapeutic strategies for cerebral ischemia warrant the characterization of 
 
vascular apoptosis to understand the implications for stroke, however, little is known 
 
about cerebrovascular apoptosis (Broughton et al. 2009). Defining the mechanisms 
 
that regulate endothelial integrity will help to identify possible vascular targets for 
 
poststroke therapy. This study investigated mechanisms underlying cell survival in 
cerebrovascular ischemia. 
The most important survival factor for the vascular endothelium is VEGF that has 
both, beneficial and negative effects on the blood-brain-barrier: Next to inhibiting 
apoptosis (Zachary 2001), VEGF promotes endothelial migration and proliferation 
(Kowanetz and Ferrara 2006; Ferrara 2009), but it also induces endothelial 
hyperpermeability (Dirnagl et al. 1999) as an early response to hypoxia (Schoch et al. 
2002). VEGF functions need to be regulated to adapt to situative responses. A 
possible candidate molecule could be the non-tyrosinkinase VEGF receptor NP-1 
that influences the interaction of VEGF with the tyrosinkinase receptor VEGFR-2 
(Soker et al. 1998 and 2002). An independent VEGF receptor function of NP-1 
(Wang et al. 2007) is still controversial (Ylä-Herttuala et al. 2007). 
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We hypothesized that NP-1 represents the fine-regulating element in the VEGF/ 
VEGF receptor system modulating the VEGF response. In this study, we found 
evidence for the enhancement of important effects of VEGF by NP-1. Apoptosis 
 
inhibition and upregulation of PARP expression induced by VEGF via VEGFR-2 were 
 
augmented by the coreceptor NP-1. VEGFR2 / NP-1-dependent PARP expression 
 
was transduced by Akt and JNK pathways and transcriptionally regulated. NP-1, 
 
VEGFR-2 and PARP expression were found to be increased in rat cerebral ischemia 
 
models in relation to apoptosis and oxidative stress. 
 
 
 
 
NP-1 is also a semaphorin receptor in neuronal cell guidance (Fujisawa and 
Kitsukawa 1998) and is expressed, next to vessels, on neurons, T-cells, dendritic 
cells (Lepelletier et al. 2007; Gu et al. 2003) and migrating cancer cells (Jia et al. 
2010). NP-1 transgene and gene deletion mouse models indicate its essential role in 
angiogenesis, capillary formation, cardiovascular development (Kitsukawa et al. 
1997; Kawasaki et al. 1999) and brain vessel formation (Kitsukawa et al. 1995). The 
role of NP-1 in disease has predominantly been investigated in tumor angiogenesis 
(Eccles and Welch 2007), but its function in (cerebro-)vascular pathologies is largely 
unknown. NP-1 expression has been related to neovascularization and angiogenesis 
in ischemic lesion remodeling in the rat or mouse model (Zhang et al. 2001; Beck et 
al. 2002), but no evidence exists on its role in acute cerebrovascular disease. 
 
 
The coreceptor function of NP-1 was supported by experiments with VEGF isoforms: 
VEGF-A(121) that binds predominantly to VEGFR-2 reduced apoptosis significantly 
less than VEGF-A(165) that binds to VEGFR-2 and NP-1 (Soker et al. 1998; 
Whitaker et al. 2001). In receptor inhibitor experiments, simultaneous inhibition of 
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VEGFR-2 and NP-1 had a greater inhibitory impact than VEGFR-2 inhibition alone, 
 
consistent with the coreceptor function of NP-1. However, NP-1 inhibition only had no 
significant effect in the presence of VEGF, explained by the molecular mechanisms 
of VEGFR-2 and NP-1 interaction: Both receptors form a complex with differential 
signaling potency, the coreceptor NP-1 displays a receptor-clustering rather than an 
affinity-converting function. VEGF-A(165) is thought to bind to VEGFR-2 and, at the 
same time, to VEGFR-2/NP-1 complexes. VEGF-A(121) only activates VEGFR-2 
(Whitaker et al. 2001; Zachary 2001), its binding to NP-1 is probably not functional 
(Pan et al. 2007). Blocking NP-1 by an inhibitor like A7R will therefore not necessarily 
lead to a reduced effect of VEGF-A(165) on EC (Starzec et al. 2006), whereas 
simultaneous inhibition of VEGFR-2 and NP-1 compared to VEGFR-2 inhibition only 
may rather demonstrate NP-1 coreceptor function (Whitaker et al. 2001). Additionally, 
NP-1 also interacts with VEGFR-2 via its cytoplasmic domain involving synectin 
(Prahst et al. 2008) so that extracellular binding of an inhibitor to NP-1 might not 
entirely block VEGFR-2/NP-1 interaction. Hence, the modulating effects of NP-1 on 
PARP regulation are better identified by VEGF isoform experiments. 
 
 
 
Colocalization of NP-1 and VEGFR-2 demonstrated by immunostaining reflects their 
functional association on EC (Soker et al. 1998; Giraudo et al. 1998; Petrova et al. 
1999). VEGF-induced perinuclear clustering of VEGFR-2 and NP-1 may originate 
from functional receptor complexes localized to endocytic vesicles containing Rab11 
(Ballmer-Hofer et al. 2011). Intracellular NP-1 may also be associated with vesiculo- 
vacuolar organelles for VEGF-induced transcellular transport (Teesalu et al. 2009). 
The expression pattern of VEGF receptors demonstrated here changed unexpectedly 
in cells undergoing programmed cell death with an almost complete disappearance 
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of immunodetectable NP-1 pointing to a loss of VEGF responsiveness of EC. NP-1 
may undergo receptor shedding by ADAM-10 releasing soluble NP-1 from EC into 
the circulation, whereas ADAM-17 is the sheddase of VEGFR-2 (Swendeman et al. 
2008). Remarkably, soluble NP-1 acts as VEGF-antagonist by binding VEGF-A(165) 
(Gagnon et al. 2000). Thus, reduction of membrane-bound NP-1 enhances the 
susceptibility of the cerebrovascular bed to apoptosis in two ways: by reduced 
enhancement of VEGFR-2 signaling and through the inhibition of VEGF functions 
through soluble NP-1. 
 
 
VEGF signaling via VEGFR-2 / NP-1 was demonstrated here to be transduced by 
 
JNK and Akt leading to transcriptional regulation of PARP expression. Anti-apoptotic 
 
signaling  pathways  of  VEGF  described  previously  include  VEGFR-2-dependent 
 
activation of phosphatidylinositol 3'-kinase / Akt (Gerber et al. 1998, Thakker et al. 
 
1999; Hörmann et al. 2011) and NP-1-dependent activation of this pathway with 
 
subsequent inactivation of p53 (Wang et al. 2007). Moreover, JNK activation was 
 
described, however it was thought to promote apoptosis counteracted by ERK 1/2 
 
(Gupta et al. 1999). Next to vasoprotection, VEGF was attributed a neuroprotective 
 
function (Kilic et al. 2006; Wang et al. 2005) exerted through Akt activation exceeding 
 
the negative early VEGF effects like vascular leakage (Kilic et al. 2006). 
 
 
 
 
VEGF induces resistance to apoptosis through PARP, as we have previously shown 
(Hörmann et al. 2011). In cerebral ischemia, the extrinsic apoptosis pathway results 
in caspase-3 activation (Zhou et al. 2004) that leads to PARP cleavage (Virag 2005; 
Boulares et al. 1999). In this study, apoptosis was induced through the adhesion 
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inhibitor cRGDfV that activates caspases and the extrinsic pathway (Al-Fakhri et al. 
2003 a) as a parallel to pathophysiological reactions in cerebral ischemia. 
Bcl-2, an inhibitor of the intrinsic pathway of apoptosis, has previously been identified 
as a target of VEGF (Gerber et al. 1998; Kim et al. 2006). In our experimental 
settings, PARP was the more prominent target of VEGF than Bcl-2. 
 
 
 
The exact mechanisms by which PARP counteracts apoptosis are still unknown, 
whether by its DNA-regenerating function or by the regulation of gene expression 
(Virag, 2005). PARP induces DNA repair counteracting pro-apoptotic stimuli and is a 
cofactor to transcription factors associated with inflammation like NF-κB and STATs 
(Aguilar-Quesada et al. 2007). However, PARP is a two-faced molecule that can 
cause necrosis when excessive cellular stress occurs (Aguilar-Quesada et al., 2007). 
Whether PARP acts anti-apoptotic, pro-inflammatory or pro-necrotic depends on the 
cell's actual activation state. PARP activity and function are controlled  by 
mechanisms that are not fully known (Virag 2005; Aguilar-Quesada et al. 2007). 
Here, we propose the modulation of VEGF-induced PARP expression through NP-1. 
 
 
 
In the rat MCAO model, vascular and neuronal NP-1 and vascular VEGFR-2 were 
upregulated within 24 hours after occlusion or occlusion-reperfusion in peri-infarct 
regions characterized by neuronal and endothelial apoptosis and detection of 
cleaved caspase-3. For the first time, this study related imminent neuro-vascular 
apoptosis to an increased expression of NP-1 and VEGFR-2. Surprisingly, NP-1 and 
VEGFR-2 were upregulated in the ipsilateral and contralateral hemisphere. In tissue 
lysates, overall hemispheral NP-1 expression was significantly higher on the 
contralateral side, possibly because of a higher number of intact vessels and neurons 
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compared to the infarct side. In histochemistry, a slightly higher number of NP-1 
expressing neurons (non-significant) and EC (significant) was demonstrated on the 
ischemic side. In the vicinity of apoptotic vessels, NP-1 and VEGFR-2 expressions 
were highly increased. 
Previous studies demonstrated murine cerebrovascular NP-1 expression (Thomas et 
al. 2008) and related NP-1 to angiogenesis during post-ischemic brain remodeling in 
longer-term rat (Zhang et al. 2001) and mouse MCAO models (Beck et al. 2002). 
Increased endothelial VEGFR-2 expression was found in the mouse MCAO model 
three days after ischemia (Beck et al. 2002), but not in rat acute or chronic cerebral 
ischemia (Hai et al. 2003; Plate et al. 1999). However, short-term changes in the 
VEGF/VEGF receptor system may be more relevant to cerebral ischemia, since it 
responds acutely to vascular impairment by VEGF upregulation in microglia and 
macrophages (Plate et al. 1999) and in neurons and pial cells after transient MCAO 
in rats (Hayashi et al. 1997). After chronic or acute cerebral hypoperfusion, the NP-1- 
binding isoform VEGF-A(165) or rat VEGF-A(164) shows a higher expression than 
VEGF-A(121) (Hai et al. 2003; Hayashi et al. 1997). In the present study, VEGF was 
demonstrated in brain vessels on the ipsi- and contralateral side possibly resulting 
from a higher local binding to VEGF receptors (Plate et al. 1999). VEGF induces the 
vascular expression of NP-1 via VEGFR-2 (Oh et al. 2002) and may thus inhibit 
apoptosis in cerebral ischemia. 
 
 
 
Vascular apoptosis is triggered by pro-apoptotic factors and radical oxygen species 
(Fisher 2008; Olmez and Ozyurt 2012) resulting from oxidative stress during cerebral 
ischemia. Oxidative stress induces catalase and SOD-1 expression (Slemmer et al. 
2008; Facchinetti et al. 1998) demonstrated here in the vessels of the ipsilateral 
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hemisphere. Exuberant oxidative stress leads to cellular energy depletion of NAD+ 
 
and ATP. During ischemia, glycogen is metabolized anaerobically generating ATP 
 
(Brucklacher et al. 2002). The reduced mean glycogen content demonstrated in 
 
ischemic brain indicates energy depletion (Brucklacher et al. 2002) which relates to 
 
an  increased  risk  for  PARP  overactivation  and  cell  death  (Virag  2005;  Aguilar- 
 
Quesada et al. 2007) in the ischemic brain. 
 
 
 
 
PARP immunoreactivity was increased in vessels and neurons after ischemia 
compared to control animals with an identical expression level of intact PARP in both 
hemispheres from whole tissue lysates. Since PARP is degraded immediately during 
apoptosis (Virag 2005; Aguilar-Quesada et al. 2007), stable expression of intact 
 
PARP (116 kD) in regions of apoptosis during cerebral ischemia indicates a net 
 
increase in PARP. The increase in PARP cleavage products (89 and 24 kD: Boulares 
 
et al. 1999) and in PARP mRNA found in the IR model, especially in the ischemic 
 
hemisphere, supports this concept. PARP expression induced by VEGF (Hörmann et 
al. 2011) may reflect a protective response to imminent vascular and neuronal 
apoptosis during ischemia. However, overactivated PARP can switch from  DNA 
repair to the enhancement of inflammation and oxidative stress causing cellular 
damage (Virag 2005; Aguilar-Quesada et al. 2007). PARP expression and activity 
therefore need stringent control through the factors regulating its production like the 
VEGF/VEGF receptor system. 
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Conclusions 
 
 
Taken together, cerebrovascular ischemia induces a widespread increase of NP-1 
 
and VEGFR-2 and the reactive upregulation of anti-apoptotic VEGF in the brain 
 
paralleled by signs of oxidative stress. VEGF induces intracellular PARP production 
 
that counteracts apoptosis. As a result of ischemia, exuberant oxidative stress leads 
 
to cellular energy depletion, a cause of PARP overactivation and necrotic cell death 
 
(Virag 2005; Aguilar-Quesada et al. 2007). To prevent PARP overactivation, the 
 
induction of PARP expression by VEGF must be controlled. NP-1 modulates the 
 
VEGF-dependent upregulation of PARP and may control the cellular response to 
 
ischemia. NP-1 therefore represents the best candidate for a key modulator ensuring 
the maintenance of endothelial and neuronal integrity in cerebrovascular diseases. 
 
 
 
Understanding  the  mechanisms  of  apoptosis  inhibition  could  ultimately  lead  to 
 
particular or supplemental therapies targeting cerebrovascular apoptosis. NP-1 is a 
 
potential target for anti-apoptotic therapeutic strategies, modulators of NP-1 function 
 
could adapt the situative response of the VEGF/VEGF receptor system to oxidative 
 
stress  during  cerebral  ischemia  and  should  be  evaluated  in  future  studies. 
 
Modulation  of  NP-1  and  PARP  function  is  a  promising  strategy  for  post-stroke 
 
treatment in the management of cerebral ischemia. 
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Figure legends 
 
 
Figure 1. Endothelial resistance to apoptosis is augmented by the vascular 
endothelial growth factor (VEGF) receptor neuropilin-1 (NP-1). (A) Pre-incubation of 
HUVEC   with   VEGF-A(165)   10ng/ml   (6d,   48h-intervals)   significantly   reduced 
apoptosis, demonstrated by annexin V/propidium iodide flow cytometry, induced by 
the αv-integrin inhibitor cRGDfV 5µg/ml compared to cells not pre-incubated with 
VEGF. VEGF-A(121) 10ng/ml that binds predominantly to VEGF receptor-2 (VEGFR- 
2) showed a significantly smaller effect on apoptosis inhibition than VEGF-A(165) 
that binds both receptors indicative of NP-1's coreceptor role in VEGF-induced 
apoptosis resistance. Data in (A) and (B) are mean +/- standard error of the mean 
(SEM)  of  4-5  independent  experiments.  Statistical  significance  of  differences  is 
indicated by the p-value (ANOVA). 
 
(B) The impact of NP-1 on apoptosis inhibition is supported by receptor antagonist 
experiments. Pre-incubation of HUVEC with VEGF-A(165) 10ng/ml over 6d inhibited 
cRGDfV-induced apoptosis; this was blocked by co-incubation with VEGFR-2 
inhibitor SU5416 10µM or the combination of SU5416 with NP-1 inhibitor A7R 10µM. 
In contrast, A7R had no effect on apoptosis inhibition in cells pre-incubated with 
VEGF-A(165) compared to incubation with VEGF and cRGDfV explained by the 
specific mechanisms of VEGFR-2/NP-1 interaction (see results and discussion 
sections). Incubations with VEGF-A(165) and inhibitors (without cRGDfV) showed no 
apoptosis induction through A7R and a small, non-significant increase in apoptosis 
through SU5416 or both inhibitors in the presence of VEGF. Control incubations with 
inhibitors alone (data not shown) showed no significant induction of apoptosis, 
incubations with inhibitors and cRGDfV had results similar to cRGDfV alone. 
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Figure 2. NP-1 increases PARP expression induced by VEGF by acting as a 
VEGFR-2 coreceptor. (A) VEGF-A(165) 10ng/ml induced a significantly stronger 
increase in PARP protein than VEGF-A(121) 10ng/ml demonstrated by Western blot 
and automated densitometry. PARP protein was normalized to β-actin as loading 
control. Additionally, VEGF-A(165) had a greater effect on PARP mRNA production 
than VEGF-A(121), quantified by real-time RT-PCR and normalized to GAPDH 
mRNA. These data indicate a coreceptor role for NP-1 augmenting VEGF/VEGFR-2- 
induced PARP expression. Data in (A) - (C) are mean +/- SEM of 3 independent 
experiments, p-values (ANOVA) are indicated. Representative blots of experiments 
are supplemented to the densitometry data. 
(B) Incubation with VEGF-A(165) and SU5416 (VEGFR-2 inhibitor) demonstrated a 
significantly reduced expression of PARP protein compared to incubation with VEGF 
alone or with A7R (NP-1 inhibitor) and VEGF. Combined incubation of A7R and 
SU5416 with VEGF-A(165) further reduced PARP protein emphasizing the 
coreceptor function of NP-1. PARP mRNA production was strongly increased by 
incubation with VEGF-A(165) and blocked by VEGF receptor inhibitors SU5416 and 
A7R.  Incubation  with  A7R  significantly  inhibited  the  VEGF-dependent  increase, 
SU5416 or both inhibitors led to a further reduction of the VEGF effect, however, the 
differences between PARP mRNA production levels of inhibitor incubations were not 
statistically significant. 
(C) VEGF-A(165) induced the expression of the anti-apoptotic intracellular protein 
Bcl-2, the expression level was significantly smaller than that of PARP protein and 
did not reach statistical significance compared to negative control. 
(D) Analysis of signal transduction revealed activation of Akt and JNK, whereas 
ERK1/2 and MAPK p38 remained unphosphorylated. Short term incubations over 
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15-120 min were carried out with VEGF-A(165) 10-100ng/ml and analyzed by 
Western blot automated densitometry of the respective phosphorylated to total 
kinase proteins. Data in (D) are means of 5 independent experiments. 
 
 
 
Figure 3. The colocalized receptors VEGFR-2 and NP-1 change their expression 
pattern upon VEGF stimulation and during apoptosis induction. In control incubations 
of HUVEC without VEGF ("contr."), VEGFR-2 and NP-1 were demonstrated on the 
endothelial cell membrane and in the cytoplasm with a disseminated distribution 
pattern and only occasional colocalization (white arrows). After incubation with 
VEGF-A(165) 10ng/ml ("VEGF"), clustering and almost complete colocalization of 
VEGFR-2 and NP-1 was demonstrated by optically sectioned immunofluorescence 
staining (ApoTome.2, Zeiss). Clusters of colocalized receptors were detectable in the 
cytoplasm indicating receptor endocytosis. Apoptosis induction with cRGDfV 5µg/ml 
("cRGD") dramatically reduced NP-1 expression leaving no NP-1 on the cell surface 
and only few clusters of NP-1 with VEGFR-2 in the perinuclear space. The VEGFR-2 
expression pattern became diffusely distributed in cells undergoing apoptosis. 
VEGFR-2 is stained green (Alexa Fluor 488), NP-1 red (Cy-3), nuclei are stained 
blue (DAPI); 600-fold magnification. The scale bar represents 100 µm. A 
representative example of 3 independent experiments is shown. 
 
 
 
Figure 4. Apoptosis of neurons and endothelial cells is detected in the rat model of 
cerebral ischemia. In the ischemia-occlusion (IO, n=3) and ischemia-reperfusion 
model (IR, n=8), apoptosis was detected by ISL assay. The number of apoptotic 
neurons and endothelial cells was significantly higher on the ischemic side of the IR 
and the IO model compared to sham-operated (n=5) and untreated controls (n=1). 
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The  panels  show  the  IR  model  stained  by  ISL  assay  presenting  examples  of 
 
analyzed neurons and vessels of the ischemic and contralateral side as well as the 
staining controls (pos: positive control, DNAse I pretreatment; neg: negative control, 
no probe). Arrowheads in the upper panels indicate ISL-positive, apoptotic neuronal 
nuclei, arrows in the lower panels indicate the vascular endothelium (200-fold 
magnification); the scale bar represents 100 µm. Data are means +/- SEM, p-values 
(ANOVA) are indicated. 
 
 
 
 
Figure 5. Cerebral ischemia of the rat is characterized by changes in NP-1 and 
PARP expression. (A) Cryotome sections of rat brains were stained by 
immunohistochemistry (alkaline phosphastase-conjugate, Fast Red). Representative 
examples from the ischemic (Is) and contralateral (Cl) hemisphere of the IR model 
and of an untreated, normal animal (No) are shown (200-fold magnification). The 
inserted panels show a close-up of the positively marked vessels at higher 
magnification. Increased VEGFR-2 and NP-1 immunoreactivity was detected on the 
endothelium of the ischemic and contralateral hemisphere in the IR model. NP-1 
immunostaining was also increased in neurons in the IR model, especially on the 
ischemic side, compared to controls. PARP immunoreactivity was increased in the 
endothelium and neurons in IR animals compared to controls. Activated, cleaved 
caspase-3 (act. casp.-3) and catalase were increased in the vascular endothelium of 
the ischemic hemishpere indicating a correlation between endothelial apoptosis, 
increased PARP and NP-1 expression with oxidative stress. Catalase (and SOD-1, 
not shown) were also moderately increased in vessels of the contralateral 
hemisphere.  As  staining  controls,  von Willebrand  factor  (positive  control  for  the 
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endothelial lining) and the negative staining control (neg. contr.) are shown. The 
scale bar represents 100 µm. 
(B) Semi-quantitative evaluation of NP-1 and PARP immunostaining revealed a 
highly significant increase in NP-1 and PARP positive endothelial and neuronal cells 
in the IR model on the ischemic (IR ischemic) and contralateral (IR contralat.) side 
compared to non-operated (no op.) and sham-operated (sham-op.) animals. An 
increased number of NP-1 and PARP positive vessels were demonstrated in the 
vicinity of regions of endothelial apoptosis. Comparison of the ischemic and the 
contralateral hemisphere in IR animals revealed a higher number of NP-1 positive 
neurons and vessels on the ischemic side, but only endothelial expression was 
significantly different between the hemispheres. PARP positive vessels were 
comparably increased in both hemispheres, but a significantly higher count of PARP 
positive neurons was found in the ischemic compared to the non-ischemic 
hemisphere. 
(C) In separately prepared whole brain tissue lysates of both hemispheres, an 
increased NP-1 protein expression in the IR model was found compared to controls. 
NP-1 expression was higher in the contralateral hemisphere than in the ischemic 
hemisphere  demonstrated  by  Western  blot  and  automated  densitometry.  Intact 
 
PARP protein (116 kD) expression  was comparably high in the IR model as in 
 
controls,  no  statistical  difference  was  found  between  the  ischemic  and  the 
 
contralateral hemisphere. PARP cleavage products 89 and 24 kD were moderately 
 
increased in the IR model, especially in the ischemic hemisphere. Representative 
 
blots of individual animals are supplemented to the densitometry data, actin detection 
 
was carried out in the same blot. 
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(D) The protein data were supported by mRNA results that showed increased PARP 
mRNA production in the IR model compared to control demonstrated by real-time 
RT-PCR and normalized to lamin A/C mRNA (the house keeping gene GAPDH, used 
in cell culture experiments, is regulated in cerebral ischemia, see methods). Data in 
(B), (C) and (D) are means +/- SEM, p-values (ANOVA) are indicated. These findings 
indicate a net increase in the production of PARP under pro-apoptotic conditions, 
since PARP is degraded during apoptosis induction. 
 
 
Figure 6. Glycogen is depleted in cerebral ischemia. Whole-mount cryostate sections 
of  rat  brain  stained  with  PAS  (periodic  acid-Schiff  reaction)  for  glycogen  were 
scanned and densitometrically evaluated. Ischemic hemispheres of the IR model 
showed a significantly reduced glycogen content compared to control, however, PAS 
staining was also slightly reduced in contralateral hemispheres and sham-operated 
animals compared to controls (the difference just missed statistical significance in 
contralateral  hemispheres).  A representative  example  of  PAS  staining for  tissue 
glycogen (red stained tissue) is demonstrated in a coronary section of a brain from an 
IR-treated animal (10-fold magnification). Red staining indicates intact glycogen 
storage. The ischemic region in the perfusion area of the A. cerebri media in the right 
hemisphere shows almost no PAS staining caused by tissue glycogen depletion, as 
indicated by a dotted line. 
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